Meta-analysis: Influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin

European Journal of Gastroenterology and Hepatology

Volumn 26, Issue 11, 2014, Pages 1189-1201

  Yee, Brittany E ^a   Nguyen, Nghia H ^a   Zhang, Bing ^a   Vutien, Philip ^c   Wong, Carrie R ^d   Lutchman, Glen A ^b   Nguyen, Mindie H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d STONY BROOK UNIVERSITY   (United States)

Author keywords

Genotype 4; Hepatitis C; Pegylated interferon and ribavirin; Sustained virologic response

Indexed keywords

PEGINTERFERON; RIBAVIRIN; ANTIVIRUS AGENT; INTERFERON;

EFFECT SIZE; EMBASE; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 4; HOST; HUMAN; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; CLASSIFICATION; DRUG COMBINATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOST PATHOGEN INTERACTION; ISOLATION AND PURIFICATION; LIVER CIRRHOSIS; METHODOLOGY; PHYSIOLOGY; VIROLOGY;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERONS; LIVER CIRRHOSIS; POLYMORPHISM, GENETIC; RESEARCH DESIGN; RIBAVIRIN; VIRAL LOAD;

EID: 84927601949     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000147     Document Type: Review

References (115)

1. [No authors listed]. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6:35-47.
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-567.
3. Wantuck JM, Ahmed A, Nguyen MH. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther 2014; 39:137-147.
4. Ramia S, Eid-Fares J. Distribution of hepatitis C virus genotypes in the Middle East. Int J Infect Dis 2006; 10:272-277.
5. Watson JP, Al-Mardini H, Awadh S., Ukabam S, Record CO. Hepatitis C virus genotypes in a cohort of Middle Eastern patients. Ann Saudi Med 1999; 19:410-412.
6. Aljumah AA, Murad MH. Pegylated versus standard interferon plus ribavirin in chronic hepatitis C genotype 4: a systematic review and meta-analysis. Hepatol Res 2013; 43:1255-1263.
7. Ghany MG, Strader DB, Thomas D.L., Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-1374.
8. Nguyen MH, Keeffe EB. Chronic hepatitis C: genotypes 4 to 9. Clin Liver Dis 2005; 9:411-426.
9. Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005; 3 (Suppl 2): S97-S101.
10. El Khayat HR, Fouad YM, El Amin H, Rizk A. A randomized trial of 24 versus 48 weeks of peginterferon alpha-2a plus ribavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response. Trop Gastroenterol 2012; 33:112-117.
11. El Makhzangy H, Esmat G, Said M., Elraziky M, Shouman S, Refai R., et al. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol 2009; 81:1576-1583.
12. El Raziky M, Fathalah WF, El-Akel WA, Salama A., Esmat G, Mabrouk M, et al. The effect of peginterferon alpha-2a vs. peginterferon alpha-2b in treatment of naive chronic hcv genotype-4 patients: a single centre Egyptian study. Hepat Mon 2013; 13:e10069.
13. Kamal SM, El Kamary SS, Shardell MD, Hashem M, Ahmed IN, Muhammadi M, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology 2007; 46:1732-1740.
14. Mauss S, Berger F, Vogel M., Pfeiffer-Vornkahl H, Alshuth U, Rockstroh J.K., et al. Treatment results of chronic hepatitis C genotype 5 and 6 infections in Germany. Z Gastroenterol 2012; 50:441-444.
15. Ahmed MM, Abdel-Salam OME, Mohammed NA, Habib D.F., HE-E Gomaa. Oxidative status and the response to pegylated-interferon alpha2a plus ribavirin in chronic genotype 4 HCV hepatitis. EXCLI Journal 2013; 12:605-615.
16. Kamal SM, Ahmed A, Mahmoud S., Nabegh L, El Gohary I, Obadan I, et al. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis. Liver Int 2011; 31:401-411.
17. Khuroo MS, Khuroo MS, Dahab ST. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2004; 20:931-938.
18. Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J., Hakam SA, et al. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 54:858-866.
19. Gilead Sciences Inc. Sovaldi [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2013.
20. Fink M, Hirschler B. Gilead offers Egypt new hepatitis C drug at 99 percent discount [Internet]. New York: Thomson Reuters; 2014.
21. Higgins JPT. Cochrane handbook for systematic reviews of interventions, version 5.1.0. Chichester: The Cochrane Collaboration; 2011.
22. Harbord RM, Higgins JPT. Meta-regression in Stata. Stata J 2008; 8:493-519.
23. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21:1559-1573.
24. Sterne J. Meta-analysis in Stata: an updated collection from the Stata Journal. College Station: StataCorp LP; 2009. p. 259.
25. Sterne JAC, Harris RJ, Harbord R.M., Steichen TJ. What meta-analysis features are available in Stata? 2013. Available at: http://www.stata.com/support/faqs/statistics/meta-analysis/. [Accessed March 2014].
26. Abdel-Rahman M, Saad Y, El-Raziky M, Zayed N., El-Akel W, Said M, et al. Hepatitis C genotype 4 with normal transaminases: correlation with fibrosis and response to treatment, a cohort Egyptian study of 4277 patients. Clin Res Hepatol Gastroenterol 2013; 37:479-484.
27. Abdo AA, Al-Ahdal MN, Khalid S.S., Helmy A., Sanai FM, Alswat K, et al. IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection. Hepatol Int 2013; 7:533-538.
28. Afifi MT, El-gohary A. Evaluation of the efficacy and safety of pegylated interferon (alpha)2a 160 mg (reiferon retard) and ribavirin combination in chronic HCV genotype 4 patients. J Gastroenterol Hepatol 2010; 25 (Suppl 2):A95.
29. Akbar HO, Al Ghamdi A, Qattan F, Fallatah H.I., Al Rumani M. Chronic hepatitis C in Saudi Arabia: three years local experience in a university hospital. Hepat Mon 2012; 12:e6178.
30. Al Ali J, Owayed S, Al-Qabandi W, Husain K., Hasan F. Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents. Ann Hepatol 2010; 9:156-160.
31. Al Ashgar H, Helmy A, Khan M.Q., Al Kahtani K, Al Quaiz M, Rezeig M, et al. Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4. Ann Saudi Med 2009; 29:4-14.
32. Al Ashgar HI, Khan MQ, Al-Ahdal M, Al Thawadi S, Helmy AS, Al Qahtani A, Sanai FM. Hepatitis C genotype 4: genotypic diversity, epidemiological profile, and clinical relevance of subtypes in Saudi Arabia. Saudi J Gastroenterol 2013; 19:28-33.
33. Al-Ali J, Siddique I, Varghese R., Hasan F. Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT. Ann Hepatol 2012; 11:186-193.
34. Al-Ashgar HI, Khan MQ, Helmy A, Al-Thawadi S, Al-Ahdal MN, Khalaf N, et al. Relationship of interferon-γ-inducible protein-10 kDa with viral response in patients with various heterogeneities of hepatitis C virus genotype-4. Eur J Gastroenterol Hepatol 2013; 25:404-410.
35. Al-Enzi SA, Ismail WA, Alsurayei S.A., Ismail E. Peginterferon alfa-2b and ribavirin therapy in Kuwaiti patients with chronic hepatitis C virus infection. East Mediterr Health J 2011; 17:669-678.
36. Alfaleh FZ, Alswat K, Helmy A., Al-hamoudi W, El-sharkawy M, Omar M., et al. The natural history and long-term outcomes in patients with chronic hepatitis C genotype 4 after interferon-based therapy. Liver Int 2013; 33:871-883.
37. Antaki N, Bibert S, Kebbewar K., Asaad F, Baroudi O, Alideeb S., et al. IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4. J Viral Hepat 2013; 20:59-64.
38. Asselah T, De Muynck S, Broët P, Masliah-Planchon J, Blanluet M, Bièche I, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012; 56:527-532.
39. De Nicola S, Aghemo A, Rumi M.G., Galmozzi E., Valenti L, Soffredini R, et al. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology 2012; 55:336-342.
40. Derbala M, Amer A, Bener A., Lopez AC, Omar M, El Ghannam M. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J Viral Hepat 2005; 12:380-385.
41. Derbala M, Rizk N, Shebl F., Alkaabi S, Eldweik N, John A., et al. Interleukin-28 and hepatitis C virus genotype-4: treatment-induced clearance and liver fibrosis. World J Gastroenterol 2012; 18:7003-7008.
42. Derbala M, Rizk NM, Al-Kaabi S, John A., Sharma M, El-dweik N, et al. The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients. Virology 2013; 444 (1-2):292-300.
43. Derbala MF, Shebl F, John A., Alkaabi S, Eldweik N, Pasic F., et al. Neutropenia and viral load decline during treatment of hepatitis C virus genotype-4 patients: the paradox of treatment modification. Hepatol Int 2012; 6:194.
44. Derbala MF, Al Kaabi SR, El Dweik NZ, Pasic F, Butt MT, Yakoob R, et al. Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage. World J Gastroenterol 2006; 12:5692-5698.
45. Derbala MF, Amer AM, Almohanadi M, John A., Amin A, John A, et al. Hepatitis C virus genotype 4 with normal transaminases: histological changes, schistosomiasis and response to treatment. J Viral Hepat 2011; 18:e258-e262.
46. Derbala MF, El Dweik NZ, Al Kaabi SR, Al-Marri AD, Pasic F, Bener AB, et al. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy. J Viral Hepat 2008; 15:591-599.
47. Diago M, Hassanein T, Rodés J, Ackrill A.M., Sedarati F. Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin. Ann Intern Med 2004; 140:72-73.
48. El Khayat HR, Fouad YM, Ahmad E.A., El Amin H, Ismael F, Rizk A. Hepatitis C virus (genotype 4)-associated mixed cryoglobulinemia vasculitis: effects of antiviral treatment. Hepatol Int 2012; 6:606-612.
49. Elefsiniotis IS, Pavlidis C, Dimitroulopoulos D., Vezali E, Mihas C, Mariolis-Sapsakos T, et al. Differential viral kinetics in treated genotype 4 chronic hepatitis C patients according to ethnicity. J Viral Hepat 2009; 16:738-742.
50. Elefsiniotis IS, Pavlidis C, Ketikoglou I., Koutsounas S, Scarmeas N, Pantazis K.D., et al. Patient's age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin. Eur J Intern Med 2008; 19:266-270.
51. Elefsiniotis IS, Vezali E, Mihas C., Saroglou G. Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin. Intervirology 2009; 52:247-251.
52. El-Khattib AA, Abdelhakam SM, Ghoraba D.M., Ibrahim WA, Sayed MM. Outcome of antiviral therapy in Egyptian hepatitis C virus (HCV) genotype 4 patients with advanced liver fibrosis. Eur J Intern Med 2012; 23:e34-e35.
53. El-Shamy A, Shoji I, El-Akel W, Bilasy S.E., Deng L., El-Raziky M, et al. NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients. J Clin Microbiol 2012; 50:3886-3892.
54. Eskander EF, Abd-Rabou AA, Yahya S.M., Shaker OG, Mohamed MS. Does interferon and ribavirin combination therapy ameliorate growth hormone deficiency in HCV genotype-4 infected patients? Clin Biochem 2012; 45 (1-2):3-6.
55. (")) in Egyptian patients with chronic hepatitis C - genotype 4. Dig Liver Dis Suppl 2009; 3:17-19.
56. Farag RE, Arafa MM, El-Etreby S, Saudy N.S., Eldeek BS, El-Alfy HA, et al. Human leukocyte antigen class I alleles can predict response to pegylated interferon/ribavirin therapy in chronic hepatitis C Egyptian patients. Arch Iran Med 2013; 16:68-73.
57. Fathalla W, El-Akel W, Salama A., Esmat G, Mabrouk M. The effect of peginterferon alpha-2a vs. peginterferon alpha-2B in treatment of naive chronic HCV genotype-4 patients: a cohort Egyptian study. Gastroenterology 2012; 142 (Suppl 1):S939.
58. Ferenci P, Laferl H, Scherzer T.M., Gschwantler M., Maieron A, Brunner H, et al. Austrian Hepatitis Study Group. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135:451-458.
59. Gad RR, Males S, El Makhzangy H, Shouman S, Hasan A., Attala M, et al. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. Liver Int 2008; 28:1112-1119.
60. Elsayed-elbatae H. Could vitamin D supplementation improve response to antiviral treatment for hepatitis C virus genotype 4? Hepatol Int 2013; 7 (Suppl 1):S343.
61. Hamdi N, El-Akel W, El-Serafy M, Esmat G, Sarrazin C., Abdelaziz AI. Transcriptional response of Mx A, PKR and SOCS3 to interferon-based therapy in HCV genotype 4-infected patients and contribution of p53 to host antiviral response. Intervirology 2012; 55:210-218.
62. Hasan F, Asker H, Al-Khaldi J, Siddique I., Al-Ajmi M, Owaid S, et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004; 99:1733-1737.
63. Ibrahim M, Gomaa W, Ibrahim Y., El Hadad H, Shatat M, Aleem A.A., et al. Nitric oxide levels and sustained virological response to pegylated-interferon alpha2a plus ribavirin in chronic HCV genotype 4 hepatitis: a prospective study. J Gastrointestin Liver Dis 2010; 19:387-392.
64. Kamal S, Ghoraba D, Nabegh L., Nasser I, Motaoe M, Sayed M.E., et al. Pegylated interferon alfa-2a vs pegylated interferon alfa-2b, plus ribavirin, for chronic hepatitis C genotype 4 patients: a randomized controlled trial. Hepatology 2009; 50 (SUPPL. 4):1025A-1026A.
65. Karatapanis S, Dimitroulopoulos D, Papastergiou V., Ketikoglou I, Elefsiniotis I, Stampori M., Skorda L, Koutsounas S. Hepatitis C genotype 4 response rate to pegylated interferon A2A or A2B and ribavirin is similar between caucasians and egyptian patients. Eur J Intern Med 2011; 22 (Suppl 1):S47.
66. Khairy M, Fouad R, Mabrouk M., El-Akel W, Awad AB, Salama R, et al. The impact of interleukin 28b gene polymorphism on the virological response to combined pegylated interferon and ribavirin therapy in chronic HCV genotype 4 infected egyptian patients using data mining analysis. Hepat Mon 2013; 13:e10509.
67. Khattab M, Eslam M, Sharwae M.A., Shatat M., Ali A, Hamdy L. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 2010; 105:1970-1977.
68. Khattab MA, Abdel-fattah ME, Eslam M., Abdelaleem A, Abdelaleem RA, Shatat M, et al. Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy. J Clin Gastroenterol 2010; 44:707-712.
69. Khattab MA, Eslam M, Shatat M., Abd-Aalhalim H, Mousa YI, Samir F, et al. Changes in adipocytokines and insulin sensitivity during and after antiviral therapy for hepatitis C genotype 4. J Gastrointestin Liver Dis 2012; 21:59-65.
70. Legrand-Abravanel F, Nicot F, Boulestin A., Sandres-Sauné K, Vinel JP, Alric L, Izopet J. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. J Med Virol 2005; 77:66-69.
71. López-Alonso G., Agreda M, Devesa MJ, Cuenca F, Suárez A, Ortega L, et al. Results of the treatment of chronic hepatitis C genotype 4a - comparative analysis with genotype 1. Rev Esp Enferm Dig 2008; 100:208-211.
72. Mahmoud M, El-Tokhy S, El-Lebedy D, Elfotouh MA, El-Arabi GH. Peripheral blood lymphocytes' DNA damage in different treatment outcomes of chronic viral C hepatitis genotype 4 infection. J Med Sci 2013; 13:353-359.
73. Marcellin P, Cheinquer H, Curescu M., Dusheiko GM, Ferenci P, Horban A, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012; 56:2039-2050.
74. Mimidis K, Papadopoulos VP, Elefsiniotis I, Koliouskas D., Ketikoglou I, Paraskevas E, et al. Hepatitis C virus survival curve analysis in naïve patients treated with peginterferon alpha-2b plus ribavirin. A randomized controlled trial for induction with high doses of peginterferon and predictability of sustained viral response from early virologic data. J Gastrointestin Liver Dis 2006; 15:213-219.
75. Monis A, Ali Monis A, Al Swaff R. Virologic response at week 8 of combined treatment as a predictor of sustained virologic response in non rapid virologic response, chronic HCV genotype 4 infected patients. Egypt J Med Human Genet 2012; 13:331-335.
76. Moucari R, Ripault MP, Martinot-Peignoux M, Voitot H., Cardoso AC, Stern C, et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009; 58:1662-1669.
77. Njouom R, Sartre MT, Timba I, Nerrienet E., Tchendjou P, Pasquier C, Rousset D. Efficacy and safety of peginterferon alpha-2a/ribavirin in treatment-naive Cameroonian patients with chronic hepatitis C. J Med Virol 2008; 80:2079-2085.
78. Omran MH, Ibrahim NE, Youssef S.S., Fatouh BE, Nabil W, El-Shami MM, El Awady MK. Relation of interleukin-1β gene to treatment response in chronic patients infected with HCV genotype 4. J Infect Dev Ctries 2013; 7:851-858.
79. Papastergiou V, Dimitroulopoulos D, Skorda L., Lisgos P, Ketikoglou I, Kostas N., Karatapanis S. Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter? J Med Virol 2012; 84:1217-1223.
80. Pasha HF, Radwan MI, Hagrass H.A., Tantawy EA, Emara MH. Cytokines genes polymorphisms in chronic hepatitis C: impact on susceptibility to infection and response to therapy. Cytokine 2013; 61:478-484.
81. Ragheb MM, Nemr NA, Kishk R.M., Mandour MF, Abdou MM, Matsuura K, et al. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4. Liver Int 2013; 34:890-895.
82. Roulot D, Bourcier V, Grando V., Deny P, Baazia Y, Fontaine H., et al. Observational VHC4 Study Group. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007; 14:460-467.
83. Saad Y, Ahmed A, Saleh D.A., Doss W. Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4. Eur J Gastroenterol Hepatol 2013; 25:920-925.
84. Saad Y, Said M, Nassar Y., Esmat GE, Shaker OG. Microsomal triglyceride transfer protein (MTP) polymorphisms as marker for prediction of response to antiviral therapy in Egyptian patients with chronic HCV genotype 4. Hepatology 2012; 56 (Suppl 1):1005A.
85. Shahin Y, Shaheen W, El Fiky H, Moawad S. A scoring model for prediction of relapse among chronic HCV genotype 4 patients treated with peg interferon and ribavirin. J Hepatol 2013; 58 (SUPPL. 1):S358-S359.
86. Shaker O, Ahmed A, Doss W., Abdel-Hamid M. MxA expression as marker for assessing the therapeutic response in HCV genotype 4 Egyptian patients. J Viral Hepat 2010; 17:794-799.
87. Shaker O, Bassiony H, El Raziky M, El-Kamary SS, Esmat G., El-Ghor AM, Mohamed MM. Human leukocyte antigen class II alleles (DQB1 and DRB1) as predictors for response to interferon therapy in HCV genotype 4. Mediators Inflamm 2013; 2013:392746.
88. Shaker O, El-Shehaby A, Fayez S., Zahra A, Marzouk S, El Raziky M. Osteopontin gene polymorphisms as predictors for the efficacy of interferon therapy in chronic hepatitis C Egyptian patients with genotype 4. Cell Biochem Funct 2013; 31:620-625.
89. Shaker OG, Eskander EF, Yahya S.M., Mohamed MS, Abd-Rabou AA. Genetic variation in BCL-2 and response to interferon in hepatitis C virus type 4 patients. Clin Chim Acta 2011; 412 (7-8):593-598.
90. Shaker OG, Sadik NA. Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin-therapy. J Gastroenterol Hepatol 2012; 27:1842-1849.
91. Shiha G, El-Etrby S, Zalata K., Samir W. Efficacy of new PEG-interferon a-2a (Reiferon Retard(registered trademark)) plus ribavirin in Egyptian patients with chronic hepatitis C genotype 4. Hepatol Int 2010; 4:187-188.
92. Shiha G, Samir W, Seif S., El-Etreby SA, Abdel-Khalek E. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients with hepatitis C virus genotype 4. Hepatology 2012; 56 (Suppl 1):1023A.
93. Stauber RE, Scherzer T, Putz-Bankuti CJ, Matejka J., Spindelboeck W, Zinober K, Beinhardt S., Wehr E, et al. Baseline vitamin D levels do not influence SVR in patients with chronic HCV genotype 1 or 4 infection undergoing peginterferon/ribavirin treatment. J Hepatol 2011; 54 (SUPPL. 1):S468-S469.
94. Taha A, Hasan M, El-Ray A, El-Ghannam M, Yilmaz N. Impact of cigarette smoking on the sustained viral response to treatment with pegylated interferon alpha-2a and ribavirin combination in male patients with chronic hepatitis C genotype 4. Hepatol Int 2012; 6:187.
95. Taha AA, El-Ray A, El-Ghannam M, Mounir B. Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C. Can J Gastroenterol 2010; 24:597-602.
96. Urquijo JJ, Diago M, Boadas J., Planas R, Solá R, Del Olmo JA, et al. Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4. Ann Hepatol 2013; 12:30-35.
97. Velosa J, Serejo F, Bana T., Redondo I, Simão A, Vale A.M., et al. Chronic hepatitis C treated with peginterferon alfa plus ribavirin in clinical practice. Hepatogastroenterology 2011; 58:1260-1266.
98. Zayed N, Awad AB, El-Akel W, Doss W., Awad T, Radwan A, Mabrouk M. The assessment of data mining for the prediction of therapeutic outcome in 3719 Egyptian patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol 2013; 37:254-261.
99. Zayed N, Esmat G, Elakel W.A., Awad T., Mabrouk M. Therapeutic outcome in 6198 interferon-naive Egyptian patients with chronic hepatitis C genotype-4: a real experience. Hepatology 2012; 56 (Suppl 1):1016A.
100. Zeidan A, El-Etreby S, Bahgat M., El-Badrawy AA, El-Etreby IMS. Pulmonary changes following the combination therapy of peginterferon alpha-2a and ribavirin for chronic hepatitis C genotype 4 infection. Hepatol Int 2012; 6:196.
101. Zekri AR, Haleem HA, Esmat G.E., Bahnassy AA, El-Din HM, Hafez MM, et al. Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4. J Viral Hepat 2007; 14:468-477.
102. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289-293.
103. Ghany MG, Kim HY, Stoddard A, Wright E.C., Seeff LB, Lok AS. HALT-C Trial Group. Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology 2011; 54:1527-1537.
104. McHutchison JG. The role of genetic markers in hepatitis C virus therapy: a major step for individualized care. Liver Int 2011; 31 (SUPPL. 1):29-35.
105. Ghany MG, Nelson DR, Strader D.B., Thomas DL, Seeff LB. American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:1433-1444.
106. Valla DC, Chevallier M, Marcellin P., Payen JL, Trepo C, Fonck M, et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999; 29:1870-1875.
107. Poynard T, McHutchison J, Manns M., Trepo C, Lindsay K, Goodman Z., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122:1303-1313.
108. McHutchison JG, Gordon SC, Schiff E.R., Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-1492.
109. Fried MW, Shiffman ML, Reddy K.R., Smith C., Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
110. Lindsay KL, Trepo C, Heintges T., Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34:395-403.
111. Thomas DL, Thio CL, Martin M.P., Qi Y., Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801.
112. Rauch A, Kutalik Z, Descombes P., Cai T, Di Iulio J, Mueller T, et al. Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138:1338-1345.
113. Abdel-Moneim AS, Bamaga MS, Shehab G.M., Abu-Elsaad AA, Farahat FM. HCV infection among Saudi population: high prevalence of genotype 4 and increased viral clearance rate. PLoS One 2012; 7:e29781.
114. Ndong-Atome GR, Makuwa M, Ouwe-Missi-Oukem-Boyer O, Pybus OG, Branger M, Le Hello S, et al. High prevalence of hepatitis C virus infection and predominance of genotype 4 in rural Gabon. J Med Virol 2008; 80:1581-1587.
115. Raptopoulou M, Touloumi G, Tzourmakliotis D., Nikolopoulou G, Dimopoulou M, Giannoulis G., et al. Significant epidemiological changes in chronic hepatitis C infection: results of the nationwide HEPNET-GREECE cohort study. Hippokratia 2011; 15:26-31.